Rhythm Pharmaceuticals Receives Positive Guidance For IMCIVREE From National Institute For Health And Care Excellence To Add Adults With Bardet-Biedl Syndrome

Benzinga · 22h ago

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the National Institute for Health and Care Excellence (NICE) has issued a positive guidance for IMCIVREE® (setmelanotide) to include adults living with genetically confirmed Bardet-Biedl syndrome (BBS).